HEALTHY LIFESTYLE




Leuprorelin acetate
Leuprorelin acetate.JPG

Leuprorelin acetate

CLINICAL USE

Treatment of advanced prostate cancer and endometriosis

DOSE IN NORMAL RENAL FUNCTION

11.25 mg every 3 months (SC depot injection, prostate cancer only)Or 3.75 mg every 4 weeks Endometriosis: 3.75 mg every month or 11.25 mg every 3 months for maximum 6 months (not to be repeated)

PHARMACOKINETICS

  • Molecular weight                           :1269.5
  • %Protein binding                           :43–49
  • %Excreted unchanged in urine     : <5 (+ metabolites)
  • Volume of distribution (L/kg)       :27 litres
  • half-life – normal/ESRD (hrs)      :3/increased

    DOSE IN RENAL IMPAIRMENT

    GFR (mL/MIN)

  • 20 to 50     : Dose as in normal renal function
  • 10 to 20     : Dose as in normal renal function
  • <10           : Dose as in normal renal function Monitor closely

    DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES

  • CAPD                :Unlikely to be dialysed. Dose as in normal renal function
  • HD                     :Unlikely to be dialysed. Dose as in normal renal function
  • HDF/high flux   :Unknown dialysability. Dose as in normal renal function
  • CAV/VVHD      :Unlikely to be dialysed. Dose as in normal renal function

    IMPORTANT DRUG INTERACTIONS

    Potentially hazardous interactions with other drugs
  • None known

    ADMINISTRATION

    Reconstition

    With diluent provided

    Route

    IM, SC depot

    Rate of Administration

    Comments

    OTHER INFORMATION

    Women on dialysis may be at greater risk of ovarian hyperstimulation, possibly because dialysis affects circulating leuprorelin concentration so endogenous gonadotrophins were still excreted. Alternatively, haemodialysis patients may have increased responsiveness to endogenous gonadotrophinsLeuprorelin acetate.
  • other drugs